05 October 2023
05 October 2023
The agreement provides Teva with a $500m upfront payment along with potential milestone-based payments of up to $1bn.
Strides earned market approval in the US as part of a larger government endeavor to address HIV worldwide.
Novartis will now focus on innovative drugs, whilst Sandoz strengthens its biosimilar business.
The optical imaging agent, FG001, is being evaluated for visualising the malignant tissue during high-grade glioma surgery.
Inhibikase is planning a Phase II trial to investigate its Abelson Tyrosine Kinase inhibitor in MSA.
Ernst and Young’s latest report finds supply chain visibility to be a viable route for pharmaceutical resilience.
The voluntary recall issued by Hospira will affect three different injectables following the potential presence of glass particles.
The initiative was created in partnership with Medicines Discovery Catapult, the Medical Research Council, and Innovate UK.
The Excellence Awards celebrate the greatest achievements and innovations in the industry, and the people and companies that are driving change.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
